Ion channel modulating compounds and uses thereof

Abstract

Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia.

1 . A method of treating or preventing arrhythmia in a warm-blooded animal, comprising administering to said animal a therapeutically effective amount of a composition comprising a compound having the following structure: 
       
         
           
           
               
               
           
         
       
       as an isolated enantiomeric or diastereomeric isomer or as a mixture thereof, or as a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, excipient or diluent. 
     
     
         2 . The method of  claim 1  wherein administration is by a route selected from the group consisting of oral, topical, parenteral, sublingual, rectal, vaginal, and intranasal. 
     
     
         3 . The method of  claim 2  wherein the parenteral administration is selected from the group consisting of subcutaneous injection, intravenous injection, intramuscular injection, epidural injection, intrasternal injection, and infusion. 
     
     
         4 . The method of  claim 2  wherein the oral administration comprises administering an oral dosage form selected from the group consisting of a powder, a granule, a compressed tablet, a pill, a capsule, a cachet, a chewing gum, a wafer, and a lozenge. 
     
     
         5 . The method of  claim 1  wherein the arrhythmia is atrial arrhythmia. 
     
     
         6 . The method of  claim 5  wherein the atrial arrhythmia is atrial fibrillation. 
     
     
         7 . The method of  claim 5  wherein the atrial arrhythmia is atrial flutter. 
     
     
         8 . The method of  claim 1  wherein the arrhythmia is ventricular arrhythmia. 
     
     
         9 . The method of  claim 8  wherein the ventricular arrhythmia is ventricular fibrillation. 
     
     
         10 . The method of  claim 9  wherein the ventricular fibrillation occurs during acute ischemia. 
     
     
         11 - 17 . (canceled) 
     
     
         18 . The method of  claim 1  wherein the compound is a mixture of isomers. 
     
     
         19 . The method of  claim 18  wherein the compound has the following structure: 
       
         
           
           
               
               
           
         
       
       or pharmaceutically acceptable salt thereof. 
     
     
         20 . The method of  claim 18  wherein the compound has the following structure: 
       
         
           
           
               
               
           
         
       
       or pharmaceutically acceptable salt thereof. 
     
     
         21 . The method of  claim 1  wherein the compound is an isolated isomer. 
     
     
         22 . The method of  claim 21  wherein the compound has the following structure: 
       
         
           
           
               
               
           
         
       
       or pharmaceutically acceptable salt thereof. 
     
     
         23 . The method of  claim 21  wherein the compound has the following structure: 
       
         
           
           
               
               
           
         
       
       or pharmaceutically acceptable salt thereof. 
     
     
         24 . The method of  claim 21  wherein the compound has the following structure: 
       
         
           
           
               
               
           
         
       
       or pharmaceutically acceptable salt thereof. 
     
     
         25 . The method of  claim 21  wherein the compound has the following structure: 
       
         
           
           
               
               
           
         
       
       or pharmaceutically acceptable salt thereof.